First Approval for Fast-Acting Lispro for Diabetes; EU OKs Oral Semaglutide First Approval for Fast-Acting Lispro for Diabetes; EU OKs Oral Semaglutide

EMA panel recommends approval of oral GLP-1 agonist semaglutide for type 2 diabetes. It has also given the thumbs up to a mealtime, or fast-acting form, of insulin lispro for adults with diabetes.International Approvals

Source: Medscape Pharmacist Headlines - January 31, 2020 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news